New Product Launches Akebia Therapeutics recently launched Vafseo, a drug for anemia related to chronic kidney disease, in Germany, Austria, and the Netherlands. This presents an opportunity for sales expansion into more regions and markets.
Investment Interest Compass Ion Advisors LLC has made a new investment in Akebia Therapeutics. This financial backing indicates investor confidence and potential growth, opening doors for strategic collaborations and partnerships.
Leadership Change Erik Ostrowski was appointed as the Senior Vice President, Chief Financial Officer, and Chief Business Officer at Akebia Therapeutics. His new role may lead to revised business strategies and connections beneficial for sales outreach.
Strategic Financing Akebia Therapeutics secured $55 million in term loan financing, showcasing financial stability and readiness for further expansion. This capital injection can provide resources for increased marketing and sales efforts.
Product Approval & Availability Vafseo tablets, approved by the FDA for treating anemia in CKD patients receiving dialysis, are set to launch in January 2025. Anticipating this launch, sales teams could prepare marketing campaigns to promote the product's availability.
41K
$1B
73$10M$50M
201$50M$100M
15K$1B
381$50M$100M
92K$1B
35K$1B
129$10M$50MAkebia Therapeutics uses 8 technology products and services including WordPress, UltiPro, Modernizr, and more. Explore Akebia Therapeutics's tech stack below.
| Akebia Therapeutics Email Formats | Percentage |
| FLast@akebia.com | 92% |
| LFirst@akebia.com | 5% |
| Last@akebia.com | 2% |
| FMLast@akebia.com | 1% |
Biotechnology ResearchMassachusetts, United States201-500 Employees
Akebia Therapeutics, Inc. is a growing biopharmaceutical company headquartered in Cambridge, Massachusetts, focused on the development and commercialization of therapeutics for people living with kidney disease. Please review our social media guidelines at: https://akebia.com/social-media-guidelines/
Company Overview
Media & News
Funding & FinancialsAkebia Therapeutics has raised a total of $37M of funding over 8 rounds. Their latest funding round was raised on Jan 30, 2024 in the amount of $37M.
Akebia Therapeutics's revenue is in the range of $50M$100M
Funding & FinancialsAkebia Therapeutics has raised a total of $37M of funding over 8 rounds. Their latest funding round was raised on Jan 30, 2024 in the amount of $37M.
Akebia Therapeutics's revenue is in the range of $50M$100M
1-888-653-2347 
support@leadiq.com